To include your compound in the COVID-19 Resource Center, submit it here.

FDA accepts Aeterna's resubmitted NDA for GHD candidate Macrilen

FDA accepted for review a resubmitted NDA from Aeterna Zentaris Inc. (TSX:AEZS;

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE